41 results about "Fucosylation" patented technology

The invention belongs to the field of food, particularly relates to a nutritional composition and application thereof in improving immune disorder, and more particularly relates to application of the nutritional composition in preparing food for improving filial generation body inflammatory factor level disorder caused by maternal immune activation. The nutritional composition comprises essential active ingredients shown as the following (i) and (ii): (i) a neutral fucosylated breast milk oligosaccharide, (ii) a neutral non-fucosylated breast milk oligosaccharide; wherein the neutral fucosylated breast milk oligosaccharide at least comprises 2 '-fucosylated lactose, and the neutral non-fucosylated breast milk oligosaccharide at least comprises lactose-N-neotetraose; in addition, in the nutritional composition, the mass ratio of the lactose-N-neotetraose to the 2 '-fucosyllactose is 1: (1-8), and the 2'-fucosyllactose and the lactose-N-neotetraose can achieve a synergistic effect to regulate filial generation immunity.

The invention discloses a method, a system and equipment for evaluating the treatment effect of 2-Flurofuse on acute kidney injury. It is found for the first time that 2FF can treat acute kidney injury through the regulation effect on core fucosylation, an EMT process, an ERK signal channel and inflammation; the invention provides a method, a system and equipment for evaluating the treatment effect of 2FF on acute kidney injury on the basis of fucosylation and a method, a system and equipment for evaluating the treatment effect of 2FF on acute kidney injury on the basis of EMT for the field. The method, the system and the equipment are used for assisting clinicians in evaluating the treatment effect of patients with acute kidney injury.

The present invention provides a fucosylated human milk oligosaccharide (HMO) for use in improving brain development and / or social emotional development in a subject wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the subject is an infant, a young child, or a child.

The invention discloses application of 2-fluorofucose in preparation of a medicine for relieving acute kidney injury, and belongs to the technical field of biology. In-vitro cell experiments and animal experiments prove that 2-fluorofucose can inhibit core fucosylation, competitively inhibit the activity of fucosyltransferase, down-regulate the expression of FUT8 and reduce the core fucosylation level in kidney tissues and renal tubular epithelial cells; by inhibiting core fucosylation, effectively reversing EMT phenotypic transformation induced by hypoxia reoxygenation or ischemia reperfusion, up-regulating E-cadherin expression, down-regulating alpha-SMA and Snail expression and reducing cell migration ability, phosphorylation activation of an ERK pathway is remarkably inhibited, and downstream inflammatory factor release and cell injury signal transduction are blocked, so that the ERK pathway can be used for inhibiting ERK pathway phosphorylation activation. The invention provides application of 2-fluorofucose to preparation of a medicine for relieving acute kidney injury. The invention provides a new choice for treating acute kidney injury, has the outstanding advantages of remarkable curative effect, high safety and the like, and has a wide application prospect.

This article describes antibodies or antigen-binding fragments that specifically bind to GPRC5D. Additionally, it includes monovalent antibodies or antigen-binding fragments that specifically bind to GPRC5D. The Fc regions of these antibodies contain K248E and T437R mutations (referred to as “RE mutations”) according to the EU numbering system. The described antibodies, when expressed in host cells lacking fucosylation capacity, exhibit enhanced antibody-dependent cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).

The present invention relates to fucosylated mammalian milk oligosaccharides (MMO) for use in a method for the prevention and / or treatment of shipping fever in animals, more particularly in farm-bred animals or domesticated animals. More particularly, the present invention relates to fucosylated mammalian milk oligosaccharides (MMO) for use in a method for the prevention and / or treatment of shipping hot pneumonia and / or shipping hot diarrhea in animals, more particularly in farm-bred animals or domesticated animals.

The invention discloses a kit for detecting plasma IgG glycosylation level and a detection method thereof, and relates to the technical field of biological detection.Plasma IgG is specifically captured through protein A, four biotinylation lectins are combined, sialylation, galactosylation, fucosylation and mannosylation levels of IgG can be synchronously and quantitatively detected, a standardized ELISA system is established, and the kit is used for detecting the plasma IgG glycosylation level. Operation is easy and convenient, repeatability is good, and the problem that multi-dimensional simultaneous detection cannot be achieved in the prior art is solved. The kit is low in cost, does not need complex instruments, is suitable for large-scale clinical popularization, and fills the market blank of commercial IgG glycosylation ELISA kits. Clinical samples of colorectal cancer prove that patients and healthy people can be effectively distinguished, in-vitro risk assessment can be realized by combining a column diagram model, the detection efficiency is excellent, and the method can be expanded to be applied to assessment and monitoring of various tumor and inflammation related diseases, and has high clinical value.

The present invention provides a fucosylated human milk oligosaccharide (HMO) for use in improving brain development and / or vision development in a subject wherein: a) the fucosylated HMO is lactose-N-fucopentasaccharide-I (LNFP-I) and the subject is an infant of up to 12 months of age; and / or b) the fucosylated HMO is A-tetrasaccharide, wherein the individual is an infant, toddler or child.

To provide a method for producing a recombinant antibody having a unique sugar chain spectrum from a genome-edited CHO host cell.SOLUTION: The method of the present invention is a method for editing fut8 genes in CHO cells suitable for suspension culturing in a serum free medium by TALEN technology, so that the edited CHO host cells can produce recombinant antibodies with unique glycan profiles. The unique glycan profile is characterized by having mainly non-fucosylated N-linked oligosaccharide chains, a low degree of heterogeneity of N-glycosylation, and uniform glycan chains. The antibodies prepared by the methods of the invention have increased ADCC activity and antibody stability.SELECTED DRAWING: Figure 10

The present invention relates to a combination and nutritional composition comprising fucosylated human milk oligosaccharides, i.e., lactose-N-fucopentasaccharide-I (LNFP-I), as the most abundant human milk oligosaccharide in the combination or the nutritional composition, and Bifidobacterium longum subsp. Infantis (Bifidobacterium infantis). The combination and the nutritional composition are useful for treating, preventing and / or inhibiting the growth of intestinal pathogens, in particular in infants.

The present application relates to methods of producing a protein in fucosylated and afucosylated forms at a predetermined ratio by partially or completely inactivating GDP-keto-6-deoxymannose-3,5-epimerase, 4-reductae (GDP-L-fucose synthase, EC 1.1.1.271) and additionally by adjusting the presence or absence of fucose source during culturing.

Recombinant blood group antigen-binding adhesin (BabA) can be used in a composition to raise humoral immune response i.e. antibodies, that target conserved structural epitopes in the fucosylated blood group antigen Lewis b (Leb) antigen binding domain in the blood group antigen-binding adhesin (BabA). Such broadly Leb-blocking antibodies can reduce the gastric mucosal attachment of Helicobacter pylori (H. pylori) to human gastric mucosa. This approach can be used for preventing and / or alleviating gastric disease in a subject diagnosed with H. pylori infection, said gastric disease chosen from gastroesophageal reflux disease, chronic active gastritis, peptic ulcer diseases, gastric ulcer disease, gastric cancer gastritis and gastric cancer, in particular gastric cancer. It also becomes possible to identify subjects that carry BabA positive H. pylori infections and subjects that are at risk of developing severe gastric disease, such as peptic ulcer diseases, gastric ulcer disease, gastritis with metaplasia and gastric cancer.

This invention relates to a synthetic human milk oligosaccharide (HMO) mixture comprising 10-30 wt% acidic HMO and 70-90 wt% neutral HMO, wherein the neutral HMO comprises 75-95 wt% fucosylated HMO based on the weight of the neutral HMO, and to the use of the HMO mixture in the treatment and / or prevention of infection.

Disclosed are methods for treating a cancer and / or modulating immune CD4+ T cell mediated therapies comprising administering to a subject a fucose. In one aspect, disclosed herein are methods of modulating major histocompatibility complex II human lymphocyte antigen (HLA)-DRB 1 expression on the surface of a cell comprising contacting the cell with an agent that modulates the amount of fucosylation on the cell; wherein an increase in fucosylation increases surface expression of HLA-DRB 1; and wherein a decrease in fucosylation decreases the surface expression of HLA-DRB 1.

The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.

Provided herein are recombinant AAT proteins having high fucosylation levels and enhanced immunomodulatory biological activity as compared to a plasma derived AAT. Further provided are compositions including the same and methods for preparation thereof.

The invention provides an afucosylated anti-FGFR2 (Fibroblast Growth Factor Receptor 2) III b antibody. Specifically, the invention provides an afucosylated anti-FGFR2IIIb antibody, a method for expressing the afucosylated anti-FGFR2IIIb antibody by using a Fut8 knockout cell, and an application of the antibody in treating diseases. The afucosylated antibodies of the present invention have enhanced binding force to Fc [gamma] RIIIa compared to conventionally expressed antibodies. The antibody disclosed by the invention can enhance the ADCC effect and has an application prospect in the field of tumor treatment.

The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The present invention relates to a de novo designed enzyme having alpha-1, 4- fucosyltransferase activity on the N-acetylglucosamine (GIcNAc) residue of Gal-β1,3-GlcNAc (lacto-N- biose, LNB), wherein said LNB resides in free form and / or is part of a saccharide. The present invention also relates to a de novo designed enzyme having alpha-1, 3-fucosyltransferase activity on the glucose (Glc) residue of Gal-β1,4-Glc (lactose). The present invention further relates to methods for the production of a fucosylated compound comprising Gal-β1,3-[Fuc-al,4]-GlcNAc and / or for the production of 3-fucosyllactose (3-FL, Gal-β1,4-[Fuc-al,3]-Glc). The present invention also provides a cell for expression of a de novo designed enzyme having alpha-1, 4-fucosyltransferase activity on the GIcNAc residue of LNB, wherein said LNB resides in free form and / or is part of a saccharide. The present invention also provides a cell for expression of a de novo designed enzyme having alpha-1, 3-fucosyltransferase activity on the Glc residue of lactose. The present invention further relates to a cell for production of a fucosylated compound comprising Gal-β1,3-[Fuc-al,4]-GlcNAc. The present invention further relates to a cell for production of 3-FL. The present invention also relates to the use of said cells in a cultivation or incubation.

A method is provided for determining the relative unpaired glycan content of an IgG antibody composition. In an exemplary embodiment, the method comprises (b) treating the IgG antibody composition with two enzymes to form a mixture of Fab fragments and Fc fragments, wherein one enzyme cleaves the antibody heavy chain at the N-terminal site of the hinge region disulfide bond and the other enzyme cleaves the β1,4 bond between core GlcNAc residues to form Fc fragments, each containing a pair of coreglycan structures; (b) separating the Fab fragments from the Fc fragments; and (c) quantifying the abundance of (i) paired non-fucosylated Fc fragments, (ii) unpaired non-fucosylated Fc fragments, (iii) paired high-mannose Fc fragments, and / or (iv) unpaired high-mannose Fc fragments to determine the relative unpaired non-fucosylated (AF) glycan content and the relative unpaired high-mannose (HM) glycan content.

The invention relates to a kit and a method for growing or fermenting oxygen-sensitive microorganisms with non-zero residual dissolved oxygen. The kit comprises a heat-stable, heat-sterilisable part A, having at least one source of nitrogen and / or peptides and at least one source of carbon; and a thermolabile part B, which can be added aseptically after cooling, providing a biomimetic carbohydrate block with an N-acetylhexosamine motif and additional components selected from fucosylated, sialylated, branched and / or sulphated structures. The method reconstitutes the medium by combining A and B, inoculates the microorganism and operates in a closed vessel without continuous purging of inert gas, maintaining dissolved oxygen below air saturation and, during part of the process, above zero and up to five milligrams per litre, in order to obtain viable biomass and / or cell-free supernatant for industrial fermentation.

Methods of determining glycan pairing content of a protein composition are provided. In exemplary embodiments, the method comprises (a) treating a sample of the protein composition with (i) a mannosidase and (ii) a β1-4 endoglycosidase, to produce a mixture of components of the protein, wherein at least some of the components comprises one or more digested glycan structures; and (b) separating the components of the mixture based on molecular weight; and (c) quantifying the abundance of glycan pairs, optionally, quantifying (i) paired afucosylated glycans, (ii) unpaired afucosylated glycans, (iii) paired high mannose glycans, and / or (iv) unpaired high mannose glycans, of the mixture. In exemplary aspects, the method comprises quantifying the relative unpaired afucosylated (AF) glycan content and / or relative unpaired high mannose (HM) glycan content of the mixture.

This invention relates to a synthetic human lactose oligosaccharide (HMO) mixture comprising 10 wt%–30 wt% acidic HMO and 70 wt%–90 wt% neutral HMO, wherein the neutral HMO comprises 75 wt%–95 wt% fucosylated HMO based on the weight of the neutral HMO, and wherein the mixture comprises at least 19 HMOs.

Provided herein are recombinant AAT proteins having high fucosylation levels and enhanced immunomodulatory biological activity as compared to a plasma derived AAT. Further provided are compositions including the same and methods for preparation thereof.

The present application belongs to the field of food, and particularly relates to a nutritional composition and its use for improving immune disorders, more particularly to the use of a nutritional composition in the preparation of a food for improving the level disorder of inflammatory factors in offspring caused by maternal immune activation; the nutritional composition comprises essential active ingredients shown as (i) and (ii): (i) neutral fucosylated human milk oligosaccharides, (ii) neutral non-fucosylated human milk oligosaccharides; wherein the neutral fucosylated human milk oligosaccharides at least comprise 2'-fucosyllactose, and the neutral non-fucosylated human milk oligosaccharides at least comprise lacto-N-neotetraose; and in the nutritional composition, the mass ratio of the lacto-N-neotetraose to the 2'-fucosyllactose is 1:(1-8). 2'-fucosyllactose and lacto-N-neotetraose can synergistically regulate offspring immunity.

The invention relates to the technical field of food nutrition and immune regulation, and provides a method for relieving food allergy. The method comprises providing an effective amount of a fucosylated human milk oligosaccharide to a subject in need of ameliorating food allergy. The fucosylated human milk oligosaccharide is a human milk oligosaccharide with a fucosylated structure, and is selected from 2 '-fucosyllactose, 3-fucosyllactose, difucosyllactose or a combination of the 2'-fucosyllactose, the 3-fucosyllactose and the difucosyllactose. According to the present invention, by promoting the improvement of the fucosylation level of the intestinal mucosa, the intestinal barrier function is enhanced, and the immune response associated with food allergy is regulated so as to prevent or alleviate the food allergy. A new technical scheme is provided for application of the fucosylated human milk oligosaccharide in the field of food allergy intervention, and the fucosylated human milk oligosaccharide has a good application prospect.

Herein are antibodies or antigen-binding fragments specifically binding to GPRC5D. Additionally, monovalent antibodies or antigen-binding fragments specifically binding to GPRC5D are also included. The Fc region of these antibodies contains K248E and T437R mutations (designated as “RE mutations”) per the EU numbering system. The described antibodies, expressed in host cells that lack fucosylation capabilities, exhibit enhanced antibody-dependent cellular cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).

The present invention relates to a method of reducing feed conversion rate (FCR) in bred animals, wherein the method comprises the step of administering (i) a fucosylated mammalian milk oligosaccharide, (ii) a sialylated mammalian milk oligosaccharide, or (iii) a fucosylated mammalian milk oligosaccharide and a sialylated mammalian milk oligosaccharide. The invention also relates to the use of (i) a fucosylated mammalian milk oligosaccharide, (ii) a sialylated mammalian milk oligosaccharide, or (iii) a fucosylated mammalian milk oligosaccharide and a sialylated mammalian milk oligosaccharide in reducing FCR in a bred animal. The invention also relates to a method of increasing the body weight of a bred animal, wherein the method comprises the step of administering fucosylated mammalian milk oligosaccharides and sialylated mammalian milk oligosaccharides.

The present invention relates to the production of complex fucosylated human milk oligosaccharides (HMOs), and in particular to the production of complex fucosylated HMO LNFP-VI or LNFP-V having five or more monosaccharide units, wherein the production method results in a product that is substantially free of LNFP-III and LNDFH-III, or LNFP-II and LNADH-II. The present disclosure also relates to genetically engineered cells and alpha-1,3-fucosyltransferases suitable for use in the production, as well as methods of producing the fucosylated HMOs.

The present invention relates to a method for providing information necessary for the diagnosis of liver cancer by measuring the percentage of fucosylated AFP (AFP-Fuc%). In the present invention, AFP present at a low concentration in serum is quantified with excellent sensitivity by performing direct mass spectrometry on total fucosylated AFP without glycan removal or the use of antibodies or lectins that recognize fucosylation sites, and hepatocellular carcinoma is detected with significantly improved accuracy compared to conventional GALAD scores using Lens culinaris agglutinin-reactive fraction (AFP-L3) as a marker. In particular, the present invention can be effectively used to establish treatment strategies early and improve patient survival rates by distinguishing early hepatocellular carcinoma from common non-tumor liver diseases with high reliability.